Summary
Steven Munatones, CEO of KAATSU Global, returns for a deeper conversation on blood flow restriction protocols and therapeutic applications. The episode emphasizes KAATSU's distinction as "additional pressure" rather than restriction, focusing on blood engorgement to trigger hormonal cascades including beta endorphins, growth hormone, IGF-1, VEGF, nitric oxide, and plasmalogens. Munatones shares groundbreaking work with military amputees showing 100% reduction in phantom pain, and discusses applications for arthritis, sleep optimization, and cognitive health. The conversation covers KAATSU's progressive cycle protocol, pain management for elderly populations, and how the technology can be integrated into daily activities for ongoing benefits.
Key Points
- KAATSU means "additional pressure" in Japanese — the approach engorges limbs with blood rather than restricting arterial flow
- KAATSU research was developed over decades with cardiologists, studying 12,000+ patients mostly in their 50s-80s with cardiac issues
- Beta endorphin release from KAATSU provides significant pain relief for amputees, with phantom pain reduction observed 100% of the time
- Growth hormone peaks 12-15 minutes after moderate KAATSU exercise, enabling strategic timing before athletic performance or public speaking
- KAATSU produces plasmalogens and ceramides that support cell wall repair and may have implications for cognitive health and dementia prevention
- The standard KAATSU cycle is 8 rounds of 30 seconds pressure / 5 seconds release at progressively increasing pressure levels
- For sleep improvement, use very light KAATSU cycles before bed to activate the parasympathetic nervous system without triggering adrenaline
- Cross-limb effects allow single-limb KAATSU to benefit amputees and immobilized patients on the opposite side of the body
Key Moments
KAATSU developed with cardiologists over decades for safety
Munatones explains that KAATSU was developed over 13 years with a team of cardiologists, studying over 12,000 patients with diverse medical conditions before launching. This clinical foundation differentiates it from other BFR products.
"Second is the equipment itself. And the third is the protocols. And the protocols are based on the research and the equipment itself. We actually did, and I studied for 13 years before we even launched Katsu with a team of cardiologists. And the reason why is"
Growth hormone and beta endorphin timing from KAATSU
Munatones describes the hormonal cascade from KAATSU, with beta endorphins produced from passive use and growth hormone peaking 12-15 minutes after moderate exercise. This enables strategic timing before performance events.
"vascular tissue engorged in blood, one of the molecules that is released or is produced as a result of that is beta endorphin. Beta endorphin is one. That's why we see a lot of pain mitigation with amputees."
Phantom pain relief for military amputees
KAATSU reduces phantom pain in amputees 100% of the time via beta endorphin release. Even single-limb KAATSU produces crossover effects, allowing amputees to feel their stump getting a workout from exercising the other arm.
"Then we observe what happens. And then we ask the question, why did that occur? Why does that amputee have less phantom pain? What is the reason why that? It doesn't happen a quarter of the time. It doesn't happen half of the time. It happens 100% of the time. So we have to understand our research is like, okay,"
KAATSU sleep protocol for better REM sleep
Munatones describes using very light KAATSU cycles before bed to activate the parasympathetic nervous system, helping users get into REM sleep faster. This has been validated with Whoop and Oura ring tracking.
"Correct. And if you think about the hormonal release of the human body anyway, a lot of that is happening while you're asleep. And so we do have what we call the jet lag protocol or the insomnia protocol for those who have problems sleeping. And that's you put on the bands."
